Are insiders buying PMCB stock?

Yes — 2 distinct insiders have bought PMCB (PharmaCyte Biotech, Inc.) on the open market, including 1 cluster buy where two or more insiders bought within a rolling window. The most recent qualifying activity was Jan 7, 2026.

How much PMCB stock have insiders bought?

Insiders have bought a combined $128.5K of PMCB across 6 open-market purchases, based on SEC Form 4 filings.

What is an insider cluster buy in PMCB?

A cluster buy is two or more distinct PharmaCyte Biotech, Inc. insiders — officers, directors, or 10% owners — each buying PMCB on the open market within a rolling window. PMCB has 1 detected cluster buy to date.

Where does this PMCB insider trading data come from?

Every figure is parsed directly from SEC Form 4 filings on EDGAR, and each purchase on this page links back to its original filing document.

PMCB insider buying

1 cluster buy

PharmaCyte Biotech, Inc. · Healthcare

When two or more insiders at PharmaCyte Biotech, Inc. buy PMCB on the open market around the same time, that clustered conviction is one of the highest-signal patterns in SEC filing data. Below is every cluster we've detected in PMCB plus the full record of qualifying open-market buys, each parsed directly from Form 4 filings and linked back to the source on SEC EDGAR.

Clusters

Distinct insiders

Total bought

$128.5K

Market cap

$7.8M

Detected clusters

Jan 5 – Jan 7, 2026
Detected Jan 7, 2026
High conviction2 insiders
Total bought
$128.5K
Market cap
$7.8M

All notable open-market buys in PMCB

Every open-market Form 4 purchase, newest first. Click an insider to see their full buying record across companies.

Date	Insider	Shares	Price	Value	Filing
Jan 7, 2026	Silverman Joshuacluster Director, CEO and President	40,000	$0.83	$33.2K	SEC ↗
Jan 7, 2026	SCHECHTER JONATHANcluster Director	20,000	$0.84	$16.8K	SEC ↗
Jan 6, 2026	Silverman Joshuacluster Director, CEO and President	30,000	$0.79	$23.7K	SEC ↗
Jan 6, 2026	SCHECHTER JONATHANcluster Director	20,000	$0.79	$15.8K	SEC ↗
Jan 5, 2026	Silverman Joshuacluster Director, CEO and President	30,000	$0.78	$23.4K	SEC ↗
Jan 5, 2026	SCHECHTER JONATHANcluster Director	20,000	$0.78	$15.6K	SEC ↗

More Healthcare stocks with insider cluster buys

All insider buying in Healthcare →

PMCB insider buying — FAQ

Are insiders buying PMCB stock?: Yes — 2 distinct insiders have bought PMCB (PharmaCyte Biotech, Inc.) on the open market, including 1 cluster buy where two or more insiders bought within a rolling window. The most recent qualifying activity was Jan 7, 2026.
How much PMCB stock have insiders bought?: Insiders have bought a combined $128.5K of PMCB across 6 open-market purchases, based on SEC Form 4 filings.
What is an insider cluster buy in PMCB?: A cluster buy is two or more distinct PharmaCyte Biotech, Inc. insiders — officers, directors, or 10% owners — each buying PMCB on the open market within a rolling window. PMCB has 1 detected cluster buy to date.
Where does this PMCB insider trading data come from?: Every figure is parsed directly from SEC Form 4 filings on EDGAR, and each purchase on this page links back to its original filing document.

How we track insider buying in PMCB

We continuously poll SEC EDGAR for new Form 4 filings and parse every open-market purchase (transaction code P). A cluster is recorded when two or more distinct insiders — officers, directors, or 10% owners — each buy PMCB within a rolling window. We track clusters at every company size, from micro-caps to mega-caps. Every figure on this page traces back to an official filing; open any row to jump straight to the source document. What counts as a cluster buy?

This page is informational and reflects public filing data. It is not investment advice or a recommendation regarding PMCB.